Ángela Gómez-Arboledas

This study identifies a conserved CD74+ macrophage niche driven by MIF-CD74 signaling that supports multi-organ metastasis in breast cancer and shows its therapeutic targeting reduces metastatic burden.

This study shows that deleting microglial C1q in young adult Alzheimer's mice reduces synaptic engulfment and preserves cognition without affecting amyloid levels.

This paper identifies Galectin-3 as a key regulator of amyloid-beta aggregation and microglial dysfunction in Alzheimer's disease, showing its role in neurotoxicity and potential as a therapeutic target.

The paper investigates how the APOE Christchurch variant affects microglial responses to amyloid and tau pathology in mouse models, finding it enhances plaque-related responses but suppresses tau-related inflammation.

This study shows that inhibiting C5aR1 reduces excessive synaptic pruning and synaptic loss in AD mouse models, improving LTP in an age and region-dependent manner.

Pharmacologic inhibition of C5aR1 suppresses disease-enhancing processes and promotes disease mitigating pathways in an aggressive model of Alzheimer's disease.

The paper shows that C5aR1 antagonism reduces amyloid load and dystrophic neurites in a mouse model of Alzheimer's disease, shifting microglial polarization toward a neuroprotective phenotype.

This study shows that modulating C5a-C5aR1 signaling in Alzheimer's disease models affects cognitive decline and gene expression related to inflammation and astrocyte activation.

This paper characterizes the 3xTg-AD mouse model of Alzheimer's Disease across its lifespan and compares it with the 5xFAD model to assess pathology and model drift.